Status:

RECRUITING

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

Lead Sponsor:

Second Affiliated Hospital of Guangzhou Medical University

Conditions:

Stage IV Ovarian Cancer

Testis Cancer, Refractory

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothel...

Detailed Description

1. Choose appropriate advanced cancer patients with Claudin6, GPC3, Mesothelin, or AXL expression, with written consent for the study; 2. Perform PBMCs apheresis from the patient and isolate NK cells,...

Eligibility Criteria

Inclusion

  • patients with advanced ovarian cancer or other cancers with expression of claudin6.
  • Life expectancy \>12 weeks
  • Adequate heart,lung,liver,kidney function
  • Available autologous transduced NK cells with greater than or equal to 20% expression of Claudin6, GPC3, Mesothelin, or AXL-CAR determined by flow-cytometry and killing of claudin6-positive targets greater than or equal to 20% in cytotoxicity assay
  • Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent. -

Exclusion

  • Had accepted gene therapy before;
  • Tumor size more than 25cm;
  • Severe virus infection such as HBV,HCV,HIV,et al
  • Known HIV positivity
  • History of liver/renal transplantation
  • Active infectious disease related to bacteria, virus,fungi,et al
  • Other severe diseases that the investigators consider not appropriate;
  • Pregnant or lactating women
  • Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day)
  • Other conditions that the investigators consider not appropriate. -

Key Trial Info

Start Date :

June 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 31 2036

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT05410717

Start Date

June 1 2022

End Date

May 31 2036

Last Update

June 25 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China